Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 5, 2012, Pages 652-659

  Ping, Szu Yuan ^a   Wu, Chia Lun ^b   Yu, Dah Shyong ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Bacillus Calmette Guerin (BCG); Combined therapy; Sutent; Synergism

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BCG VACCINE; COMPLEMENTARY DNA; LIPOCORTIN 5; MESSENGER RNA; PROPIDIUM IODIDE; PROTEIN BCL 2; SUNITINIB; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CELL ASSAY; CELL DEATH; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCG VACCINE; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866775191     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.07.001     Document Type: Article

References (23)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Health Statistics in Taiwan (2006). Part II. Statistics on Causes of Death, Department of Health, Executive Yuan, R.O.C. (Taiwan).
3. Cookson M.S., Herr H.W., Zhang Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-Year outcome. J Urol 1997, 158:62-67.
4. Thanhauser A., Bohle A., Schneider B., et al. The induction of bacillus Calmette-Guerin activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 1995, 40:103-108.
5. Patard J.J., Muscatelli-Groux B., Saint F., et al. Evaluation of local immune response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. Br J Urol 1996, 78:709-714.
6. Luo Y., Chen X., Downs T.M., et al. IFN-α 2b enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 1999, 162:2399-2405.
7. Hedges W., Agace M., Svensson H., et al. Uroepithelial cells are part of a mucosal cytokine network. Infect Immunol 1994, 62:2315-2321.
8. Izawa J.I., Sweeney P., Perrotte P., et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various anti-angiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002, 8:1258-1270.
9. Fauconnet S., Lascombe I., Chabannes E., et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002, 277:23534-23543.
10. Kausch I., Bohle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2003, 41:15-29.
11. Demetri G.D., van Oosterom A.T., Garret C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial. Lancet 2006, 368:1329-1338.
12. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115-124.
13. Cherrington J.M., Strawn L.M., Shawver L.K. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents. Advances in Cancer Research 2000, LXXIX:1-38. Academic Press, San Diego, CA. 1st ed. G. Klein, G.F. vande Woude (Eds.).
14. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77:527-543.
15. Laird A.D., Christensen J.G., Li G., et al. SU6668 inhibits Flk-1/KDR and PDGRFb in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002, 16:681-690.
16. Chou T.C. Derivation and properties of Michaelis-Menton type and Hill type equations for reference ligands. J Theor Biol 1976, 59:253-276.
17. Siddiqui I.A., Adhami V.M., Afaq F., et al. Modulation of phosphatidylinositol-3-kinase/protein kinase B and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells. J Cell Biochem 2004, 91:232-242.
18. Liu L., Zhu D., Gao R., Guo H. Expression of vascular endothelial growth factor, receptor KDR, and p53 protein in transitional cell carcinoma of the bladder. Urol Int 2008, 81:72-76.
19. Elfiky A.A., Rosenberg J.E. Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009, 11:244-249.
20. Froehner M., Hakenberg O.W., Wirth M.P. Molecular therapy in urologic oncology. Urol Int 2007, 79:1-7.
21. Silay M.S., Miroglu C. Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects. Hypotheses 2007, 69:892-895.
22. Sonpavde G., Jian W., Liu H., et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009, 27:391-399.
23. Bradley D.A., Dunn R., Nanus D., et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design. Clin Genitourin Cancer 2007, 5:460-463.